MX357837B - Métodos para inhibir el crecimiento tumoral mediante receptor il - 6 antagonizante. - Google Patents

Métodos para inhibir el crecimiento tumoral mediante receptor il - 6 antagonizante.

Info

Publication number
MX357837B
MX357837B MX2014004886A MX2014004886A MX357837B MX 357837 B MX357837 B MX 357837B MX 2014004886 A MX2014004886 A MX 2014004886A MX 2014004886 A MX2014004886 A MX 2014004886A MX 357837 B MX357837 B MX 357837B
Authority
MX
Mexico
Prior art keywords
methods
antagonist
tumor growth
antagonizing
receptor
Prior art date
Application number
MX2014004886A
Other languages
English (en)
Other versions
MX2014004886A (es
Inventor
Zhang Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2014004886A publication Critical patent/MX2014004886A/es
Publication of MX357837B publication Critical patent/MX357837B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para inhibir o atenuar crecimiento tumoral en un sujeto administrando un antagonista IL-6 al sujeto. En ciertas modalidades, los métodos de la invención se usan para inhibir el crecimiento de un tumor resistente a anti-VEGF en un sujeto. El antagonista IL-8 puede ser, v.gr., un anticuerpo que se une específicamente a SL-6R. El antagonista 11-6 puede ser administrado en combinación con un antagonista VEGF y/o un antagonista EGFR.
MX2014004886A 2011-11-10 2012-11-09 Métodos para inhibir el crecimiento tumoral mediante receptor il - 6 antagonizante. MX357837B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US201261613538P 2012-03-21 2012-03-21
PCT/US2012/064311 WO2013071016A2 (en) 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing il-6 receptor

Publications (2)

Publication Number Publication Date
MX2014004886A MX2014004886A (es) 2014-07-09
MX357837B true MX357837B (es) 2018-07-26

Family

ID=47179020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004886A MX357837B (es) 2011-11-10 2012-11-09 Métodos para inhibir el crecimiento tumoral mediante receptor il - 6 antagonizante.

Country Status (20)

Country Link
US (3) US20130122003A1 (es)
EP (1) EP2776468B1 (es)
JP (3) JP6144689B2 (es)
KR (1) KR101718748B1 (es)
CN (1) CN103930443B (es)
AR (1) AR088671A1 (es)
AU (2) AU2012335596B2 (es)
BR (1) BR112014011211A2 (es)
CA (1) CA2853836C (es)
IL (2) IL231854A (es)
IN (1) IN2014CN02923A (es)
JO (1) JO3370B1 (es)
MX (1) MX357837B (es)
MY (1) MY163953A (es)
RU (1) RU2648150C2 (es)
SG (1) SG11201401286QA (es)
TW (3) TWI604852B (es)
UY (1) UY34444A (es)
WO (1) WO2013071016A2 (es)
ZA (1) ZA201402414B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2953698A1 (en) * 2014-06-28 2015-12-30 Kodiak Sciences Inc. Dual pdgf/vegf antagonists
WO2016196377A1 (en) * 2015-05-29 2016-12-08 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CN112203679A (zh) * 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US11965176B2 (en) 2018-03-14 2024-04-23 Hunan Siweikang Therapeutics Co. Ltd Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN113677356A (zh) * 2019-01-07 2021-11-19 湖南思为康医药有限公司 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
DE69229482T2 (de) 1991-04-25 1999-11-18 Chugai Seiyaku K.K., Tokio/Tokyo Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP0800829B2 (en) 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
BRPI0011407B8 (pt) * 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
WO2002036164A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent abaissant le taux sanguin de vegf contenant un antagoniste de il-6 en tant que principe actif
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
PT1639013E (pt) * 2003-07-02 2012-12-03 Innate Pharma Anticorpos contra receptor nk pan-kir2dl e a sua utilização em diagnóstico e terapêutica
TWI350175B (en) 2003-10-17 2011-10-11 Chugai Pharmaceutical Co Ltd Mesothelioma therapeutic agent
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
MY159787A (en) * 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
CN102438653B (zh) * 2008-11-25 2019-04-23 奥尔德生物制药公司 预防或治疗恶病质、虚弱、疲劳和/或发烧il-6拮抗剂
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Also Published As

Publication number Publication date
RU2648150C2 (ru) 2018-03-22
MX2014004886A (es) 2014-07-09
BR112014011211A2 (pt) 2017-04-25
JO3370B1 (ar) 2019-03-13
US20140322215A1 (en) 2014-10-30
CN103930443B (zh) 2017-08-04
MY163953A (en) 2017-11-15
WO2013071016A2 (en) 2013-05-16
WO2013071016A3 (en) 2013-07-25
KR101718748B1 (ko) 2017-03-22
IL248620A0 (en) 2016-12-29
US9409990B2 (en) 2016-08-09
TW201332569A (zh) 2013-08-16
CA2853836C (en) 2019-07-23
US20130122003A1 (en) 2013-05-16
TWI604852B (zh) 2017-11-11
AU2018203666A1 (en) 2018-06-14
AU2012335596A1 (en) 2014-05-22
JP2014534237A (ja) 2014-12-18
CA2853836A1 (en) 2013-05-16
US20170022279A1 (en) 2017-01-26
JP2018083841A (ja) 2018-05-31
TW201716776A (zh) 2017-05-16
KR20140095481A (ko) 2014-08-01
RU2014118739A (ru) 2015-12-20
UY34444A (es) 2013-05-31
IL231854A (en) 2016-11-30
ZA201402414B (en) 2015-03-25
CN103930443A (zh) 2014-07-16
IL231854A0 (en) 2014-05-28
SG11201401286QA (en) 2014-05-29
TW201806620A (zh) 2018-03-01
AU2012335596B2 (en) 2018-05-17
JP2017095489A (ja) 2017-06-01
JP6144689B2 (ja) 2017-06-07
EP2776468B1 (en) 2018-01-24
EP2776468A2 (en) 2014-09-17
JP6283754B2 (ja) 2018-02-21
IN2014CN02923A (es) 2015-07-03
AR088671A1 (es) 2014-06-25

Similar Documents

Publication Publication Date Title
MX357837B (es) Métodos para inhibir el crecimiento tumoral mediante receptor il - 6 antagonizante.
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
WO2014031610A8 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK1212214A1 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) 1(csf1r)
MX368068B (es) Antagonista de il-4r para usarse para tratar la poliposis nasal.
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX363193B (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
HK1208233A1 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) 1(csf1r)
EA201301025A1 (ru) Преодоление устойчивости к ингибиторам пути erbb
MY186099A (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
NZ626610A (en) Antibodies that bind csf1r
SG10201807042YA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
NZ629913A (en) Anti-ox40 antibodies and methods of using the same
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
NZ706751A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
MX368653B (es) Anticuerpos anti-il-23p19.
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3

Legal Events

Date Code Title Description
FG Grant or registration